Literature DB >> 4052961

Extraintestinal cancers in inflammatory bowel disease.

A J Greenstein, R Gennuso, D B Sachar, T Heimann, H Smith, H D Janowitz, A H Aufses.   

Abstract

The case histories of 1961 patients with inflammatory bowel disease (IBD), 1227 with Crohn's disease (CD) and 734 with ulcerative colitis (UC), have been studied for the incidence of extraintestinal malignant neoplasms. There were 54 extraintestinal cancers in 51 patients: 28 patients with CD and 23 with UC; 25 men and 26 women. There were 9 breast, 7 skin, 15 reticuloendothelial, 11 genitourinary, 3 lung, 3 perianal, 2 pancreatic islet cell, and several miscellaneous cancers. The number of patient-years from the onset of disease to the last date of follow-up was calculated for men and women with each form of IBD. The observed number (O) of neoplasms was recorded. The expected number (E) of neoplasms was derived from the Department of Health, Education, and Welfare (DHEW) incidence figures for the same neoplasms that occurred in a standard age- and sex-matched population. The O/E ratio was then calculated for each type of cancer as well as for the entire series. There were no statistically significant increases in overall O/E ratios of extraintestinal cancers for either CD (0.76) or UC (1.32). On the other hand, several specific types of cancer did appear to occur with a frequency that was significantly greater than expected. These cancers were classified into two groups. The first group included reticuloendothelial neoplasms. There was an excess of leukemias in UC (P less than 0.005) and an excess of lymphomas in both UC and CD (P less than 0.005). The second group included three squamous cell cancers of the perianal region, an incidence 30 times greater than expected, and two squamous cell cancers of the vagina, also in excess of the expected number. Lymphoma, leukemia, and squamous cell cancers have been reported to occur in excess in immunosuppressed or irradiated patients. It may therefore be speculated that the apparently increased incidence of these neoplasms in the patients with ileitis and colitis might be related to immunologic deficiencies associated with IBD, to the long-term administration of steroids or other immunosuppressive medications that were given to most of the patients or, possibly, to increased exposure to ionizing radiation. The apparently increased incidence of perianal and vaginal cancers of the squamous variety might be a consequence of the combined effects of chronic inflammatory disease involving these areas and primary immune suppression.

Entities:  

Mesh:

Year:  1985        PMID: 4052961     DOI: 10.1002/1097-0142(19851215)56:12<2914::aid-cncr2820561232>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  34 in total

1.  Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low.

Authors:  R J Farrell; Y Ang; P Kileen; D S O'Briain; D Kelleher; P W Keeling; D G Weir
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

Review 2.  A perspective on inflammatory bowel disease in the child and adolescent at the turn of the millennium.

Authors:  C Haller; J Markowitz
Journal:  Curr Gastroenterol Rep       Date:  2001-06

Review 3.  Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models.

Authors:  Aya M Westbrook; Akos Szakmary; Robert H Schiestl
Journal:  Mutat Res       Date:  2010-03-16       Impact factor: 2.433

Review 4.  A case of combined primary biliary cirrhosis, ulcerative colitis and chronic myelocytic leukemia.

Authors:  K Akahoshi; Y Miyata; M Hashimoto; S Koga; Y Chijiiwa; T Misawa; E Suematsu; J Nishimura; H Nawata
Journal:  Gastroenterol Jpn       Date:  1992-04

Review 5.  Is there truly a risk of lymphoma from biologic therapies?

Authors:  Erica Dommasch; Joel M Gelfand
Journal:  Dermatol Ther       Date:  2009 Sep-Oct       Impact factor: 2.851

Review 6.  Risk of cancer in ulcerative colitis.

Authors:  A Ekbom
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

7.  Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up.

Authors:  Renato Caviglia; Mentore Ribolsi; Marina Rizzi; Sara Emerenziani; Maria Laura Annunziata; Michele Cicala
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

Review 8.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 9.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 10.  Simultaneous development of Crohn's disease and myelodysplastic syndrome progressing to acute myelocytic leukemia in a patient with a normal karyotype.

Authors:  T Tani; Y Sakai; Y Shirai; M Ohtake; K Hatakeyama
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.